- Rating
- 1
- Confidence
- 4
- Informativeness
- 1
- Presentation
- 3
- Soundness
- 1
Read review
Paper summary
This paper combines histopathological and transcriptomic information for survival prediction. Modality-specific representations are mapped to risk scores using separate Cox models, and a second Cox model combines these scores.
Critical strengths
1. A compact and modular fusion stage. The final Cox model combines only two modality-specific risk scores, keeping the fusion stage low-dimensional and separating modality-specific prediction from risk aggregation. This simplicity makes the approach a useful reference for evaluating more complex fusion strategies. It is a practical strength, although its contribution to my overall assessment is modest because simplicity alone does not establish better generalization or reduced overfitting.
2. Controlled fusion ablations and consistently positive mean results. Section 4.5 states that the fusion variants use identical modality-specific representations, helping separate the choice of fusion strategy from encoder differences. The proposed model also achieves higher mean C-indices than the included unimodal models across all four cohorts. Together, these results provide preliminary evidence of practical value and justify examining the approach beyond a single dataset, although the reliability of the improvements requires further clarification.
Critical weaknesses
1. The methodological contribution is not established relative to direct prior work. The central procedure—independently predicting modality-specific risks and fitting another Cox model to combine them—already appears in the “Late fusion” approach of Steyaert et al., 2023. The remaining components, including ssGSEA, multi-head self-attention, ConvNeXt, PCA, and penalized Cox regression, are established techniques. The manuscript does not identify a substantive new mechanism or isolate the value of its particular encoder choices. This is consequential because the paper is presented as a methodological contribution, but its technical advance over an existing risk-level fusion pipeline remains unclear.
2. The comparisons do not substantiate competitiveness against recent methods. The evaluation omits directly relevant approaches such as LD-CVAE (CVPR 2025), SlotSPE (ICLR 2026), and MoHD (Medical Image Analysis 2026). SlotSPE is particularly relevant to the motivation of compressing high-dimensional multimodal inputs, while LD-CVAE includes complete-modality evaluation. Representative comparisons under matched inputs, endpoints, splits, and tuning conditions are needed. This omission is consequential because strong empirical evidence could establish the value of a simple existing strategy, but the current benchmark does not provide that evidence or support the SOTA claim.
Questions for authors
-
Why is breast cancer the central application? The architecture and pathway representation appear broadly applicable across cancers. A disease-specific architecture is not necessary, but what unresolved breast cancer prognosis problem motivates this study? Can the authors establish disease-level value through relevant subgroup analyses or incremental prediction beyond clinical variables?
-
How is independence maintained throughout the two-stage training procedure? Are the meta-Cox training inputs generated through out-of-fold predictions within each outer training set? Are encoder training/fine-tuning, normalization, PCA, and hyperparameter selection confined to the appropriate training partitions? Please provide the complete patient-level validation workflow.
-
How reliable are the reported improvements and stability claims? On BRCA, the improvement over the WSI-only model is 0.005. Can the authors report paired confidence intervals for performance differences? Section 3.5 mentions bootstrap confidence intervals, but these are not presented in the main results. Moreover, the proposed model’s BRCA standard deviation is higher than those of concatenation and mean fusion. How does this support the claim of reduced variance? The log-rank tests establish risk-group separation, rather than superiority over competing models.
-
What claim is the multi-cancer evaluation intended to validate?
Survival prediction is defined with respect to a target population and endpoint. If models are fitted and evaluated separately within LUAD, BLCA, and KIRC, these experiments assess the reuse of the modeling pipeline for different cancer-specific prediction tasks. They do not establish generalization of the breast cancer prognostic model. What conclusion about the stated breast cancer task follows from these additional experiments, and on what basis are they described as “external validation”? Please distinguish applicability of the framework across tasks from generalization of a fitted prognostic model within its intended patient population. -
How are modality contributions interpreted? Section 4.4 infers greater histopathological contribution from larger meta-Cox coefficients. Were the input risk scores standardized before fusion? Please report the coefficients and their uncertainty, since coefficient magnitudes depend on input scale and do not directly measure modality importance.
-
Can the experimental setup be made reproducible? Please specify the final matched sample and event counts, survival endpoint, patch extraction and aggregation settings, encoder pretraining/fine-tuning, MHA configuration, PCA dimensionality, and regularization/tuning procedure.